Search

Your search keyword '"Riera Mestre, A"' showing total 123 results

Search Constraints

Start Over You searched for: Author "Riera Mestre, A" Remove constraint Author: "Riera Mestre, A" Topic business Remove constraint Topic: business
123 results on '"Riera Mestre, A"'

Search Results

1. Translational medicine in hereditary hemorrhagic telangiectasia

2. Síndromes de sobrecrecimiento relacionados con PIK3CA (PROS): Conocimiento nuevo de enfermedades conocidas

3. PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19

4. Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation

5. Edoxaban for the Long‐Term Therapy of Venous Thromboembolism: Should the Criteria for Dose Reduction be Revised?

6. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study

7. Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project

8. Satisfactory treatment of mucocutaneous lesions in hereditary hemorrhagic telangiectasia patients with dual pulsed dye laser and neodymium: yttrium–aluminum–garnet

9. Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism

10. Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19

11. Medical management of haemorrhagic hereditary telangiectasia in adult patients

12. Tratamiento de la telangiectasia hemorrágica hereditaria en el paciente adulto

13. Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial

14. Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19: a case series

15. Catheter-directed therapies in patients with pulmonary embolism: predictive factors of in-hospital mortality and long-term follow-up

16. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

17. Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia

18. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona

19. Timing and characteristics of venous thromboembolism after noncancer surgery

20. Predictors of active cancer thromboembolic outcomes

21. Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry

22. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

23. Non-retrieved inferior vena cava filters: causes and long-term follow-up

24. Angiogenesis, hereditary hemorrhagic telangiectasia and COVID-19

25. D-dimer dynamics in hospitalized COVID-19 patients: potential utility for diagnosis of pulmonary embolism

26. Outcome of patients with acute symptomatic pulmonary embolism and psychiatric disorders

27. Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness

28. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

29. Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism

30. Blood test dynamics in hospitalized COVID-19 patients: Potential utility of D-dimer for pulmonary embolism diagnosis

31. Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry

32. Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: A meta-analysis

33. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score

34. Registro informatizado de la telangiectasia hemorrágica hereditaria (Registro RiHHTa) en España: objetivos, métodos y resultados preliminares

35. Gender differences in hereditary hemorrhagic telangiectasia severity

36. Systolic blood pressure and mortality in acute symptomatic pulmonary embolism

37. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial

38. PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1

39. Letter to the Editor: mTOR-Inhibitor-Based Immunosuppression Following Liver Transplantation for Hereditary Hemorrhagic Telangiectasia

40. Role of rivaroxaban in the prevention of atherosclerotic events

41. Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry

42. Risk of recurrent venous thromboembolism after acute pulmonary embolism: Role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis

43. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients

44. Gastrointestinal Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia: Risk Factors and Endoscopic Findings

45. Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism

46. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism

47. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy

48. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

49. P2610Residual pulmonary obstruction and persistent right ventricular dysfunction as predictors of recurrent venous thromboembolism: a systematic review and meta-analysis

50. Medication regimen complexity: A new challenge

Catalog

Books, media, physical & digital resources